Skip to main content

Replagal FDA Approval Status

FDA Approved: No
Brand name: Replagal
Generic name: agalsidase alfa
Company: Shire plc
Treatment for: Fabry Disease

Replagal (agalsidase alfa) is an enzyme replacement therapy in development for Fabry disease.

Development timeline for Replagal

Dec 22, 2009Shire Submits Biologics License Application for Replagal With the U.S. Food and Drug Administration

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.